Niranib (Niraparib) 100 mg

Indicated for the maintenance treatment of adult patients with:

• Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
• First-line maintenance treatment for advanced ovarian cancer.

Dosage Form: 100 mg Capsules.

⚠️ CRITICAL DOSING RULE (Weight & Platelets):

The starting dose is individualized to reduce side effects:

• 300 mg (3 caps) daily: For patients weighing ≥ 77 kg AND platelet count ≥ 150,000/µL.
• 200 mg (2 caps) daily: For patients weighing < 77 kg OR platelet count < 150,000/µL.

🌙 Tip: Take at bedtime to manage potential nausea.

• Pregnancy and breastfeeding (embryo-fetal toxicity).
• Severe bone marrow suppression.
• Hypersensitivity to Niraparib.

Regular blood tests (CBC) and blood pressure monitoring are mandatory:

• 🩸 Thrombocytopenia: Low platelet count (risk of bleeding). This is the most common dose-limiting toxicity.
• Anemia & Neutropenia.
• Hypertension: High blood pressure.
• Nausea and fatigue.